0000000000374772

AUTHOR

Marina De Vega Martínez

showing 2 related works from this author

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

2021

AdultMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)prospective cohortMEDLINEDermatologyregistryimmunosuppressive agentsSeverity of Illness IndexCOVID-19 (Malaltia)ArticleCohort StudiesInternal medicinePandemicPsoriasisHumansMedicinebiologic therapyRegistriesAgedbusiness.industryIncidenceIncidence (epidemiology)COVID-19COVID-19 Psoriasis biologic therapy immunosuppressive agents pharmacovigilance prospective cohort registryMiddle AgedSpainpharmacovigilanceFemalebusinessPsoriasi -- TractamentCohort studyJournal of the American Academy of Dermatology
researchProduct